Home Cart Sign in  
Chemical Structure| 52286-59-6 Chemical Structure| 52286-59-6
Chemical Structure| 52286-59-6

Ginsenoside Re

CAS No.: 52286-59-6

Ginsenoside Re is a panaxatriol saponin that has diverse in vitro and in vivo effects, including vasorelaxant, antioxidant, antihyperlipidemic, and angiogenic actions.

Synonyms: Panaxoside Re; Ginsenoside B2; NSC 308877

4.5 *For Research Use Only !

Cat. No.: A149220 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
100mg łËó¶ÊÊ Inquiry Inquiry
250mg łÍ§¶ÊÊ Inquiry Inquiry
1g łÇÇî¶ÊÊ Inquiry Inquiry
5g ł§ďÿ¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 100mg

    łËó¶ÊÊ

  • 250mg

    łÍ§¶ÊÊ

  • 1g

    łÇÇî¶ÊÊ

  • 5g

    ł§ďÿ¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of [ Ginsenoside Re ]

CAS No. :52286-59-6
Formula : C48H82O18
M.W : 947.15
SMILES Code : C[C@@]12[C@@]([H])([C@](C)([C@]3([C@H](C2)O[C@@H]([C@@H]4O[C@H]5[C@@H]([C@@H]([C@H]([C@@H](O5)C)O)O)O)O[C@@H]([C@H]([C@@H]4O)O)CO)[H])CC[C@@H](C3(C)C)O)C[C@H]([C@]6([C@]1(CC[C@@]6([C@@](C)(O[C@@H]7O[C@@H]([C@H]([C@@H]([C@H]7O)O)O)CO)CC/C=C(C)\C)[H])C)[H])O
Synonyms :
Panaxoside Re; Ginsenoside B2; NSC 308877
MDL No. :MFCD00133369
InChI Key :PWAOOJDMFUQOKB-WCZZMFLVSA-N
Pubchem ID :441921

Safety of [ Ginsenoside Re ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of [ Ginsenoside Re ]

MAPK
pyroptosis
TLR

Isoform Comparison

Biological Activity

Target
  • JNK

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.06mL

0.21mL

0.11mL

5.28mL

1.06mL

0.53mL

10.56mL

2.11mL

1.06mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Wang L, Yuan D, et al. Ginsenoside Re Promotes Nerve Regeneration by Facilitating the Proliferation, Differentiation and Migration of Schwann Cells via the ERK- and JNK-Dependent Pathway in Rat Model of Sciatic Nerve Crush Injury. Cell Mol Neurobiol. 2015 Aug;35(6):827-40.

[2]Sukrittanon S, Watanapa WB, Ruamyod K. Ginsenoside Re enhances small-conductance Ca(2+)-activated K(+) current in human coronary artery endothelial cells. Life Sci. 2014 Oct 12;115(1-2):15-21.

[3]Cao G, Su P, Zhang S, et al. Ginsenoside Re reduces Aβ production by activating PPARγ to inhibit BACE1 in N2a/APP695 cells. Eur J Pharmacol. 2016;793:101-108

[4]Wang QW, Yu XF, Xu HL, Zhao XZ, Sui DY. Ginsenoside Re Improves Isoproterenol-Induced Myocardial Fibrosis and Heart Failure in Rats. Evid Based Complement Alternat Med. 2019;2019:3714508. Published 2019 Jan 1

[5]Dang DK, Shin EJ, Kim DJ, et al. Ginsenoside Re protects methamphetamine-induced dopaminergic neurotoxicity in mice via upregulation of dynorphin-mediated κ-opioid receptor and downregulation of substance P-mediated neurokinin 1 receptor. J Neuroinflammation. 2018;15(1):52. Published 2018 Feb 21

[6]Lee GH, Lee WJ, Hur J, Kim E, Lee HG, Seo HG. Ginsenoside Re Mitigates 6-Hydroxydopamine-Induced Oxidative Stress through Upregulation of GPX4. Molecules. 2020;25(1):188. Published 2020 Jan 2

[7]Gao Y, Gao CY, Zhu P, et al. Ginsenoside Re inhibits vascular neointimal hyperplasia in balloon-injured carotid arteries through activating the eNOS/NO/cGMP pathway in rats. Biomed Pharmacother. 2018;106:1091-1097

 

Historical Records

Categories